Intravascular hemolysis and the pathophysiology of sickle cell disease
Gregory J. Kato, … , Martin H. Steinberg, Mark T. Gladwin
Gregory J. Kato, … , Martin H. Steinberg, Mark T. Gladwin
Published March 1, 2017
Citation Information: J Clin Invest. 2017;127(3):750-760. https://doi.org/10.1172/JCI89741.
View: Text | PDF
Review

Intravascular hemolysis and the pathophysiology of sickle cell disease

Abstract

Hemolysis is a fundamental feature of sickle cell anemia that contributes to its pathophysiology and phenotypic variability. Decompartmentalized hemoglobin, arginase 1, asymmetric dimethylarginine, and adenine nucleotides are all products of hemolysis that promote vasomotor dysfunction, proliferative vasculopathy, and a multitude of clinical complications of pulmonary and systemic vasculopathy, including pulmonary hypertension, leg ulcers, priapism, chronic kidney disease, and large-artery ischemic stroke. Nitric oxide (NO) is inactivated by cell-free hemoglobin in a dioxygenation reaction that also oxidizes hemoglobin to methemoglobin, a non–oxygen-binding form of hemoglobin that readily loses heme. Circulating hemoglobin and heme represent erythrocytic danger-associated molecular pattern (eDAMP) molecules, which activate the innate immune system and endothelium to an inflammatory, proadhesive state that promotes sickle vaso-occlusion and acute lung injury in murine models of sickle cell disease. Intravascular hemolysis can impair NO bioavailability and cause oxidative stress, altering redox balance and amplifying physiological processes that govern blood flow, hemostasis, inflammation, and angiogenesis. These pathological responses promote regional vasoconstriction and subsequent blood vessel remodeling. Thus, intravascular hemolysis represents an intrinsic mechanism for human vascular disease that manifests clinical complications in sickle cell disease and other chronic hereditary or acquired hemolytic anemias.

Authors

Gregory J. Kato, Martin H. Steinberg, Mark T. Gladwin

×

Figure 2

Contribution of intravascular hemolysis to vasculopathy and vasoocclusion.

Options: View larger image (or click on image) Download as PowerPoint
Contribution of intravascular hemolysis to vasculopathy and vasoocclusio...
Intravascular hemolysis produces free hemoglobin, which drives Fenton reactions to produce oxidants and scavenges NO by a dioxygenation reaction. Intravascular hemolysis also releases red cell arginase 1 into plasma, where it can deplete plasma L-arginine (L-Arg), the required substrate for NO production by eNOS. Oxidized hemoglobin releases free heme, which can activate release of placenta growth factor (PIGF) and endothelin-1 (ET-1). These combined pathways contribute to chronic vasculopathy, platelet activation, and pulmonary hypertension. Heme also primes the innate immune system to acute rises in endogenous (HMGB1) and exogenous (LPS) ligands of TLR4. These in turn activate production of ROS, neutrophil extracellular traps (NETs), and downstream activation of the inflammasome, producing inflammatory cytokines and other mediators that promote expression of adhesion receptors and ligands on endothelium and blood cells. Intravascular hemolysis also releases adenine nucleotides, including ATP and ADP, which further contributes to platelet activation. There is also some evidence that adenosine binds receptors on red cells, resulting in increased 2,3-diphosphoglycerate and sphingosine-1-phosphate, associated with lower oxygen affinity of hemoglobin (not shown). Proteins on the surface of the activated endothelium (P-selectin, E-selectin, VCAM1, ICAM1) interact with adhesive platelets, neutrophils, and sickle erythrocytes, producing vasoocclusion and acute chest syndrome. Intravascular hemolysis also releases asymmetric dimethylarginine, which inhibits eNOS. CRP, C-reactive protein; SAA, serum amyloid A; Orn, ornithine. Adapted with permission from Gladwin, et al., Journal of Clinical Investigation (150).